secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0001082554-22-000021
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics Q2 2022 revenue up 5% to $466.9M; net income down 33%
-------------------------------------------------------------------------

- Total revenues $466.9M (+5% YoY); net income $116.0M ($2.41 diluted EPS) vs $172.6M ($3.65) in Q2 2021.
- Tyvaso sales $201.0M (+31%) from PH-ILD label expansion; ~500 additional Tyvaso patients in Q2.
- Share-based compensation $65.5M (+125%), driven by STAP expense from 31% stock price increase.
- FDA approved Tyvaso DPI in May 2022 for PAH and PH-ILD; commercial shipments began in June.
- CMS updated Tyvaso coverage for PH-ILD effective June 5, 2022, supporting further patient growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255422000021/0001082554-22-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255422000021/uthr-20220803.htm
  HTML page:      https://secwatch.observer/filing/0001082554-22-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer